In the Keynote 158 vulvar cancer cohort, 83.2% showed a PDL-1 CPS >1 with an overall response rate of 10.9% for a pembrolizumab mono therapy and a median duration of response of 20.4 months [38]. This evidence concerns the gene CD274 and vulva cancer.